Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Beats on EPS, Stock Up 0.76%

Ligand Pharmaceuticals reported a strong earnings per share, significantly exceeding expectations, which contributed to a modest increase in stock price. The lack of revenue data leaves some uncertainty, but management's positive outlook suggests they are on a solid path. Investors may view the EPS beat as a sign of operational strength, despite the absence of detailed revenue figures.